Meanwhile, the content of intestinal metabolite butyrate was compared to reflect the regulatory effects of these three drugs on gut microbiota
GLP-1 therapies are no longer fringe
In April 2025, the New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression in people with non-relapsing secondary progressive multiple sclerosis (nrSPMS), where there are currently no treatment options approved
The treatment preserved colon length and reduced histological epithelial injury, outcomes linked to the suppression of IL-1 expression ( GLP-1 also modulates local inflammation through specialized cell populations
Archived from the original on 4 November 2014
Incorporating foods like lean meats, fish, eggs, and plant-based protein sources into your meals can make a noticeable difference in skin elasticity